The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose

Molecular Therapy

Volumn 25, Issue 4, 2017, Pages 880-891

  Kumar, Sandeep R P ^a   Hoffman, Brad E ^a   Terhorst, Cox ^b   de Jong, Ype P ^c   Herzog, Roland W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Harvard Medical Center   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

adeno associated virus; CD8+ T cell; gene therapy; hepatitis; liver; tolerance

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; OVALBUMIN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR; CYTOKINE; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE RECEPTOR; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; EMBRYO; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; LIVER; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TRANSGENE; UPREGULATION; VIRAL GENE THERAPY; ADMINISTRATION AND DOSAGE; ANIMAL; CLASSIFICATION; DEPENDOPARVOVIRUS; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; MEMORY; METABOLISM; PHENOTYPE; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, VIRAL; B7-H1 ANTIGEN; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DEPENDOVIRUS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNE TOLERANCE; LIVER; MALE; MEMORY; MICE; PHENOTYPE; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; T-CELL ANTIGEN RECEPTOR SPECIFICITY; TRANSDUCTION, GENETIC;

EID: 85016950516     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.02.014     Document Type: Article

References (72)

1. 1 Thomson, A.W., Knolle, P.A., Antigen-presenting cell function in the tolerogenic liver environment. Nat. Rev. Immunol. 10 (2010), 753–766.
2. 2 Gao, B., Jeong, W.I., Tian, Z., Liver: an organ with predominant innate immunity. Hepatology 47 (2008), 729–736.
3. 3 Crispe, I.N., Immune tolerance in liver disease. Hepatology 60 (2014), 2109–2117.
4. 4 Cao, O., Dobrzynski, E., Wang, L., Nayak, S., Mingle, B., Terhorst, C., Herzog, R.W., Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 110 (2007), 1132–1140.
5. 5 Bowen, D.G., Zen, M., Holz, L., Davis, T., McCaughan, G.W., Bertolino, P., The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J. Clin. Invest. 114 (2004), 701–712.
6. 6 Mingozzi, F., Liu, Y.L., Dobrzynski, E., Kaufhold, A., Liu, J.H., Wang, Y., Arruda, V.R., High, K.A., Herzog, R.W., Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Invest. 111 (2003), 1347–1356.
7. 7 Ziegler, R.J., Lonning, S.M., Armentano, D., Li, C., Souza, D.W., Cherry, M., Ford, C., Barbon, C.M., Desnick, R.J., Gao, G., et al. AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. Mol. Ther. 9 (2004), 231–240.
8. 8 Lüth, S., Huber, S., Schramm, C., Buch, T., Zander, S., Stadelmann, C., Brück, W., Wraith, D.C., Herkel, J., Lohse, A.W., Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs. J. Clin. Invest. 118 (2008), 3403–3410.
9. 9 Sack, B.K., Herzog, R.W., Terhorst, C., Markusic, D.M., Development of gene transfer for induction of antigen-specific tolerance. Mol. Ther. Methods Clin. Dev., 1, 2014, 14013.
10. 10 Nathwani, A.C., Gray, J.T., McIntosh, J., Ng, C.Y.C., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E.G., Davidoff, A.M., Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109 (2007), 1414–1421.
11. 11 Nathwani, A.C., Reiss, U.M., Tuddenham, E.G.D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371 (2014), 1994–2004.
12. 12 Cooper, M., Nayak, S., Hoffman, B.E., Terhorst, C., Cao, O., Herzog, R.W., Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Hum. Gene Ther. 20 (2009), 767–776.
13. 13 Markusic, D.M., Hoffman, B.E., Perrin, G.Q., Nayak, S., Wang, X., LoDuca, P.A., High, K.A., Herzog, R.W., Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol. Med. 5 (2013), 1698–1709.
14. 14 Hoffman, B.E., Martino, A.T., Sack, B.K., Cao, O., Liao, G., Terhorst, C., Herzog, R.W., Nonredundant roles of IL-10 and TGF-β in suppression of immune responses to hepatic AAV-factor IX gene transfer. Mol. Ther. 19 (2011), 1263–1272.
15. 15 Breous, E., Thimme, R., Potential of immunotherapy for hepatocellular carcinoma. J. Hepatol. 54 (2011), 830–834.
16. 16 Yoshio, S., Kanto, T., Host-virus interactions in hepatitis B and hepatitis C infection. J. Gastroenterol. 51 (2016), 409–420.
17. 17 Rehermann, B., Chang, K.M., McHutchinson, J., Kokka, R., Houghton, M., Rice, C.M., Chisari, F.V., Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J. Virol. 70 (1996), 7092–7102.
18. 18 Protzer, U., Maini, M.K., Knolle, P.A., Living in the liver: hepatic infections. Nat. Rev. Immunol. 12 (2012), 201–213.
19. 19 Thimme, R., Oldach, D., Chang, K.M., Steiger, C., Ray, S.C., Chisari, F.V., Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194 (2001), 1395–1406.
20. 20 Radziewicz, H., Ibegbu, C.C., Fernandez, M.L., Workowski, K.A., Obideen, K., Wehbi, M., Hanson, H.L., Steinberg, J.P., Masopust, D., Wherry, E.J., et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J. Virol. 81 (2007), 2545–2553.
21. 21 Golden-Mason, L., Palmer, B., Klarquist, J., Mengshol, J.A., Castelblanco, N., Rosen, H.R., Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J. Virol. 81 (2007), 9249–9258.
22. 22 Zhang, Z., Zhang, J.Y., Wherry, E.J., Jin, B., Xu, B., Zou, Z.S., Zhang, S.Y., Li, B.S., Wang, H.F., Wu, H., et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 134 (2008), 1938–1949 1949.e1–3.
23. 23 Wuensch, S.A., Spahn, J., Crispe, I.N., Direct, help-independent priming of CD8+ T cells by adeno-associated virus-transduced hepatocytes. Hepatology 52 (2010), 1068–1077.
24. 24 Asabe, S., Wieland, S.F., Chattopadhyay, P.K., Roederer, M., Engle, R.E., Purcell, R.H., Chisari, F.V., The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J. Virol. 83 (2009), 9652–9662.
25. 25 Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12 (2006), 342–347.
26. 26 Mingozzi, F., Maus, M.V., Hui, D.J., Sabatino, D.E., Murphy, S.L., Rasko, J.E., Ragni, M.V., Manno, C.S., Sommer, J., Jiang, H., et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13 (2007), 419–422.
27. 27 Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D.C., Chowdary, P., Riddell, A., Pie, A.J., Harrington, C., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365 (2011), 2357–2365.
28. 28 Buggert, M., Tauriainen, J., Yamamoto, T., Frederiksen, J., Ivarsson, M.A., Michaëlsson, J., Lund, O., Hejdeman, B., Jansson, M., Sönnerborg, A., et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog., 10, 2014, e1004251.
29. 29 McLane, L.M., Banerjee, P.P., Cosma, G.L., Makedonas, G., Wherry, E.J., Orange, J.S., Betts, M.R., Differential localization of T-bet and Eomes in CD8 T cell memory populations. J. Immunol. 190 (2013), 3207–3215.
30. 30 Popescu, I., Pipeling, M.R., Shah, P.D., Orens, J.B., McDyer, J.F., T-bet:Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control. J. Immunol. 193 (2014), 5709–5722.
31. 31 Iwai, Y., Terawaki, S., Ikegawa, M., Okazaki, T., Honjo, T., PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. 198 (2003), 39–50.
32. 32 Dong, H., Zhu, G., Tamada, K., Flies, D.B., van Deursen, J.M., Chen, L., B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity 20 (2004), 327–336.
33. 33 Lukens, J.R., Cruise, M.W., Lassen, M.G., Hahn, Y.S., Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model. J. Immunol. 180 (2008), 4875–4884.
34. 34 Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R., Ferguson, T.A., Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270 (1995), 1189–1192.
35. 35 Pender, M.P., Activation-induced apoptosis of autoreactive and alloreactive T lymphocytes in the target organ as a major mechanism of tolerance. Immunol. Cell Biol. 77 (1999), 216–223.
36. 36 Di Marco, R., Xiang, M., Zaccone, P., Leonardi, C., Franco, S., Meroni, P., Nicoletti, F., Concanavalin A-induced hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency. Autoimmunity 31 (1999), 75–83.
37. 37 Erhardt, A., Biburger, M., Papadopoulos, T., Tiegs, G., IL-10, regulatory T cells, and Kupffer cells mediate tolerance in concanavalin A-induced liver injury in mice. Hepatology 45 (2007), 475–485.
38. 38 Ertl, H., The RAC: double, double, toil, and trouble?. Mol. Ther. 17 (2009), 397–399.
39. 39 Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121 (2013), 2224–2233.
40. 40 Herzog, R.W., Hemophilia gene therapy: caught between a cure and an immune response. Mol. Ther. 23 (2015), 1411–1412.
41. 41 Perrin, G.Q., Zolotukhin, I., Sherman, A., Biswas, M., de Jong, Y.P., Terhorst, C., Davidoff, A.M., Herzog, R.W., Dynamics of antigen presentation to transgene product-specific CD4(+) T cells and of Treg induction upon hepatic AAV gene transfer. Mol. Ther. Methods Clin. Dev., 3, 2016, 16083.
42. 42 Ziegler, R.J., Cherry, M., Barbon, C.M., Li, C., Bercury, S.D., Armentano, D., Desnick, R.J., Cheng, S.H., Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A. Mol. Ther. 15 (2007), 492–500.
43. 43 Shin, E.C., Park, S.H., Demino, M., Nascimbeni, M., Mihalik, K., Major, M., Veerapu, N.S., Heller, T., Feinstone, S.M., Rice, C.M., Rehermann, B., Delayed induction, not impaired recruitment, of specific CD8+ T cells causes the late onset of acute hepatitis C. Gastroenterology 141 (2011), 686–695 695.e1.
44. 44 Trautmann, L., Janbazian, L., Chomont, N., Said, E.A., Gimmig, S., Bessette, B., Boulassel, M.R., Delwart, E., Sepulveda, H., Balderas, R.S., et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12 (2006), 1198–1202.
45. 45 Boettler, T., Panther, E., Bengsch, B., Nazarova, N., Spangenberg, H.C., Blum, H.E., Thimme, R., Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J. Virol. 80 (2006), 3532–3540.
46. 46 Urbani, S., Amadei, B., Tola, D., Pedrazzi, G., Sacchelli, L., Cavallo, M.C., Orlandini, A., Missale, G., Ferrari, C., Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J. Hepatol. 48 (2008), 548–558.
47. 47 Yamamoto, T., Price, D.A., Casazza, J.P., Ferrari, G., Nason, M., Chattopadhyay, P.K., Roederer, M., Gostick, E., Katsikis, P.D., Douek, D.C., et al. Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. Blood 117 (2011), 4805–4815.
48. 48 Blackburn, S.D., Shin, H., Haining, W.N., Zou, T., Workman, C.J., Polley, A., Betts, M.R., Freeman, G.J., Vignali, D.A., Wherry, E.J., Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10 (2009), 29–37.
49. 49 Bengsch, B., Seigel, B., Ruhl, M., Timm, J., Kuntz, M., Blum, H.E., Pircher, H., Thimme, R., Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog., 6, 2010, e1000947.
50. 50 Ye, B., Liu, X., Li, X., Kong, H., Tian, L., Chen, Y., T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis., 6, 2015, e1694.
51. 51 Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H., Freeman, G.J., Ahmed, R., Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006), 682–687.
52. 52 Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., Wolchok, J.D., Hersey, P., Joseph, R.W., Weber, J.S., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369 (2013), 134–144.
53. 53 Mühlbauer, M., Fleck, M., Schütz, C., Weiss, T., Froh, M., Blank, C., Schölmerich, J., Hellerbrand, C., PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J. Hepatol. 45 (2006), 520–528.
54. 54 Grakoui, A., John Wherry, E., Hanson, H.L., Walker, C., Ahmed, R., Turning on the off switch: regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. J. Hepatol. 45 (2006), 468–472.
55. 55 Sen, D.R., Kaminski, J., Barnitz, R.A., Kurachi, M., Gerdemann, U., Yates, K.B., Tsao, H.W., Godec, J., LaFleur, M.W., Brown, F.D., et al. The epigenetic landscape of T cell exhaustion. Science 354 (2016), 1165–1169.
56. 56 Pauken, K.E., Sammons, M.A., Odorizzi, P.M., Manne, S., Godec, J., Khan, O., Drake, A.M., Chen, Z., Sen, D.R., Kurachi, M., et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354 (2016), 1160–1165.
57. 57 Turner, S.J., Russ, B.E., Can T cells be too exhausted to fight back?. Science 354 (2016), 1104–1105.
58. 58 Intlekofer, A.M., Takemoto, N., Wherry, E.J., Longworth, S.A., Northrup, J.T., Palanivel, V.R., Mullen, A.C., Gasink, C.R., Kaech, S.M., Miller, J.D., et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 6 (2005), 1236–1244.
59. 59 Paley, M.A., Kroy, D.C., Odorizzi, P.M., Johnnidis, J.B., Dolfi, D.V., Barnett, B.E., Bikoff, E.K., Robertson, E.J., Lauer, G.M., Reiner, S.L., Wherry, E.J., Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338 (2012), 1220–1225.
60. 60 Joshi, N.S., Cui, W., Dominguez, C.X., Chen, J.H., Hand, T.W., Kaech, S.M., Increased numbers of preexisting memory CD8 T cells and decreased T-bet expression can restrain terminal differentiation of secondary effector and memory CD8 T cells. J. Immunol. 187 (2011), 4068–4076.
61. 61 Kao, C., Oestreich, K.J., Paley, M.A., Crawford, A., Angelosanto, J.M., Ali, M.A., Intlekofer, A.M., Boss, J.M., Reiner, S.L., Weinmann, A.S., Wherry, E.J., Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat. Immunol. 12 (2011), 663–671.
62. 62 Lin, S.W., Hensley, S.E., Tatsis, N., Lasaro, M.O., Ertl, H.C., Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J. Clin. Invest. 117 (2007), 3958–3970.
63. 63 Limmer, A., Ohl, J., Kurts, C., Ljunggren, H.G., Reiss, Y., Groettrup, M., Momburg, F., Arnold, B., Knolle, P.A., Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat. Med. 6 (2000), 1348–1354.
64. 64 Horst, A.K., Neumann, K., Diehl, L., Tiegs, G., Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells. Cell. Mol. Immunol. 13 (2016), 277–292.
65. 65 Keir, M.E., Butte, M.J., Freeman, G.J., Sharpe, A.H., PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26 (2008), 677–704.
66. 66 Nakamoto, N., Kaplan, D.E., Coleclough, J., Li, Y., Valiga, M.E., Kaminski, M., Shaked, A., Olthoff, K., Gostick, E., Price, D.A., et al. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 134 (2008), 1927–1937 1937.e1–2.
67. 67 Seifert, A.M., Zeng, S., Zhang, J.Q., Kim, T.S., Cohen, N.A., Beckman, M.J., Medina, B.D., Maltbaek, J.H., Loo, J.K., Crawley, M.H., et al. PD-1/PD-L1 blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors. Clin. Cancer Res. 23 (2017), 454–465.
68. 68 Liu, Y.L., Wagner, K., Robinson, N., Sabatino, D., Margaritis, P., Xiao, W., Herzog, R.W., Optimized production of high-titer recombinant adeno-associated virus in roller bottles. Biotechniques 34 (2003), 184–189.
69. 69 Kim, J.M., Rasmussen, J.P., Rudensky, A.Y., Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8 (2007), 191–197.
70. 70 Dobrzynski, E., Mingozzi, F., Liu, Y.L., Bendo, E., Cao, O., Wang, L., Herzog, R.W., Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. Blood 104 (2004), 969–977.
71. 71 Jellison, E.R., Kim, S.K., Welsh, R.M., Cutting edge: MHC class II-restricted killing in vivo during viral infection. J. Immunol. 174 (2005), 614–618.
72. 72 Rogers, G.L., Hoffman, B.E., Optimal immunofluorescent staining for human factor IX and infiltrating T cells following gene therapy for hemophilia B. J. Genet. Syndr. Gene Ther.(Suppl 1), 2012, 012.